FMP
Visa Inc.
V
NYSE
Visa Inc. operates as a payments technology company worldwide. The company facilitates digital payments among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. In addition, the company offers card products, platforms, and value-added services. It provides its services under the Visa, Visa Electron, Interlink, VPAY, and PLUS brands. Visa Inc. has a strategic agreement with Ooredoo to provide an enhanced payment experience for Visa cardholders and Ooredoo customers in Qatar. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California.
341.25 USD
3.74 (1.1%)
Mr. Ryan M. McInerney
Financial Services
Financial - Credit Services
NYSE
Visa Inc. operates as a payments technology company worldwide. The company facilitates digital payments among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. In addition, the company offers card products, platforms, and value-added services. It provides its services under the Visa, Visa Electron, Interlink, VPAY, and PLUS brands. Visa Inc. has a strategic agreement with Ooredoo to provide an enhanced payment experience for Visa cardholders and Ooredoo customers in Qatar. Visa Inc. was founded in 1958 and is ...
0001403161
US92826C8394
92826C839
PO Box 8999
650 432 3200
US
28,800
Mar 19, 2008
0001403161
NYSE
Financial - Credit S...
Financial Services
92826C839
US92826C8394
US
341.25
0.94
7.22M
666.85B
-
252.7-366.54
260.71
-
-
-
-
34.4
-
https://usa.visa.com
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Andrew Wynn
16 hours ago
Novartis AG, listed as NYSE:NVS, is a leading global healthcare company known for its innovative pharmaceuticals. On April 29, 2025, NVS reported earnings per share of $2.28, surpassing the estimated $2.12. Despite this, the company generated revenue of approximately $13.23 billion, slightly below the estimated $13.81 billion. Novartis has increased its 2025 financial outlook following a significant rise in its core operating profit, which surged by 23% year-over-year. This impressive growth w...
Gordon Thompson
a day ago
Virtus Investment Partners, Inc. (NYSE: VRTS) is a company that provides investment management services. It operates through various subsidiaries and offers a range of investment strategies to individual and institutional clients. The company competes with other investment management firms in the financial sector. On April 28, 2025, Benjamin Budish from Barclays set a price target of $150 for VRTS. At that time, VRTS was trading at $153.28, which is about 2.14% higher than the target price. Dur...
Tony Dante
2 days ago
NOV Inc. (NYSE:NOV) is a global leader in the design, construction, and sale of systems and products for the oil and gas, industrial, and renewable energy sectors. The company operates through three main segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. NOV provides a wide array of services, including drilling optimization and hydraulic fracture stimulation equipment. The consensus price target for NOV's stock has shown an upward trend over the past year,...
Parth Sanghvi
2 days ago
Huawei is set to disrupt the AI semiconductor space with the launch of its new 910C AI chip, a move that could intensify competition for Nvidia (NASDAQ:NVDA) in China’s booming artificial intelligence market. Huawei’s Ascend 910C: A Strategic Play Against Nvidia According to a Reuters report, Huawei plans to mass ship its Ascend 910C AI processors to Chinese customers as early as next month. Key points: The 910C chip is described as an architectural evolution rather than a revolutionary...
Parth Sanghvi
2 days ago
China’s Huawei Technologies is preparing a major move in the artificial intelligence race, as it gets ready to test its most powerful AI chip yet — the Ascend 910D. This could be a significant step in replacing Nvidia’s (NASDAQ: NVDA) dominance in China’s high-end AI processor market. What’s Happening Huawei has approached Chinese tech firms to test the technical capabilities of the Ascend 910D, according to the Wall Street Journal. First samples of the chip are expected to be delivered...
Gordon Thompson
3 days ago
MVB Financial Corp. (NASDAQ:MVBF) is a financial services company that operates in the Mid-Atlantic region and internationally. It offers a variety of services, including traditional and mortgage banking, as well as financial technology (Fintech) services. The company provides deposit accounts, loans, credit lines, non-deposit investment services, and fraud prevention services. Analysts have maintained a consistent price target of $20 for MVBF over the past year. This stability indicates a ste...
Rayan Ahmad
4 days ago
AbbVie Inc. (NYSE:ABBV) is a prominent player in the pharmaceutical industry, known for its innovative treatments and therapies. The company focuses on developing and marketing advanced medicines, particularly in immunology, oncology, and virology. AbbVie competes with other large pharmaceutical companies like Pfizer and Merck, striving to maintain its position through continuous research and development. On April 25, 2025, AbbVie reported earnings per share (EPS) of $2.46, surpassing the estim...
Stuart Mooney
5 days ago
Novo Nordisk (NYSE:NVO) is a leading pharmaceutical company based in Denmark, known for its innovative diabetes and weight management medications. The company has a strong presence in the GLP-1 diabetes market, with popular drugs like Ozempic and Wegovy. However, it faces stiff competition from major rivals like Eli Lilly, which also targets the diabetes and obesity drug markets. On April 24, 2025, DBS Bank downgraded Novo Nordisk to a "Sell" rating, with the stock priced at $62.63. This downgr...